BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 30905408)

  • 1. Updated meta-analysis of closure of patent foramen ovale versus medical therapy after cryptogenic stroke.
    Nasir UB; Qureshi WT; Jogu H; Wolfe E; Dutta A; Majeed CN; Tan WA
    Cardiovasc Revasc Med; 2019 Mar; 20(3):187-193. PubMed ID: 30905408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Closure, Anticoagulation, or Antiplatelet Therapy for Cryptogenic Stroke With Patent Foramen Ovale: Systematic Review of Randomized Trials, Sequential Meta-Analysis, and New Insights From the CLOSE Study.
    Turc G; Calvet D; Guérin P; Sroussi M; Chatellier G; Mas JL;
    J Am Heart Assoc; 2018 Jun; 7(12):. PubMed ID: 29910193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Percutaneous closure versus medical therapy alone for cryptogenic stroke patients with a patent foramen ovale: meta-analysis of randomized controlled trials.
    Pickett CA; Villines TC; Ferguson MA; Hulten EA
    Tex Heart Inst J; 2014 Aug; 41(4):357-67. PubMed ID: 25120387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A meta-analysis of transcatheter closure of patent foramen ovale versus medical therapy for prevention of recurrent thromboembolic events in patients with cryptogenic cerebrovascular events.
    Pineda AM; Nascimento FO; Yang SC; Kirtane AJ; Sommer RJ; Beohar N
    Catheter Cardiovasc Interv; 2013 Nov; 82(6):968-75. PubMed ID: 23832613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcatheter Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke: A Meta-Analysis of Randomized Controlled Trials.
    Darmoch F; Al-Khadra Y; Soud M; Fanari Z; Alraies MC
    Cerebrovasc Dis; 2018; 45(3-4):162-169. PubMed ID: 29597192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrent Stroke Reduction with Patent Foramen Ovale Closure versus Medical Therapy Based on Patent Foramen Ovale Characteristics: A Meta-Analysis of Randomized Controlled Trials.
    Garg A; Thawabi M; Rout A; Sossou C; Cohen M; Kostis JB
    Cardiology; 2019; 144(1-2):40-49. PubMed ID: 31574522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Case for Selective Patent Foramen Ovale Closure After Cryptogenic Stroke.
    Wiktor DM; Carroll JD
    Circ Cardiovasc Interv; 2018 Mar; 11(3):e004152. PubMed ID: 29870380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Percutaneous Closure of Patent Foramen Ovale in Patients with Cryptogenic Stroke - An Updated Comprehensive Meta-Analysis.
    Sitwala P; Khalid MF; Khattak F; Bagai J; Bhogal S; Ladia V; Mukherjee D; Daggubati R; Paul TK
    Cardiovasc Revasc Med; 2019 Aug; 20(8):687-694. PubMed ID: 30282597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patent foramen ovale transcatheter closure vs. medical therapy on recurrent vascular events: a systematic review and meta-analysis of randomized controlled trials.
    Rengifo-Moreno P; Palacios IF; Junpaparp P; Witzke CF; Morris DL; Romero-Corral A
    Eur Heart J; 2013 Nov; 34(43):3342-52. PubMed ID: 23847132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcomes of patent foramen ovale closure or medical therapy after cryptogenic stroke: A meta-analysis of randomized trials.
    Abdelaziz HK; Saad M; Abuomara HZ; Nairooz R; Pothineni NVK; Madmani ME; Roberts DH; Mahmud E
    Catheter Cardiovasc Interv; 2018 Jul; 92(1):176-186. PubMed ID: 29726616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patent foramen ovale closure, antiplatelet therapy or anticoagulation in patients with patent foramen ovale and cryptogenic stroke: a systematic review and network meta-analysis incorporating complementary external evidence.
    Mir H; Siemieniuk RAC; Ge L; Foroutan F; Fralick M; Syed T; Lopes LC; Kuijpers T; Mas JL; Vandvik PO; Agoritsas T; Guyatt GH
    BMJ Open; 2018 Jul; 8(7):e023761. PubMed ID: 30049703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke.
    Mas JL; Derumeaux G; Guillon B; Massardier E; Hosseini H; Mechtouff L; Arquizan C; Béjot Y; Vuillier F; Detante O; Guidoux C; Canaple S; Vaduva C; Dequatre-Ponchelle N; Sibon I; Garnier P; Ferrier A; Timsit S; Robinet-Borgomano E; Sablot D; Lacour JC; Zuber M; Favrole P; Pinel JF; Apoil M; Reiner P; Lefebvre C; Guérin P; Piot C; Rossi R; Dubois-Randé JL; Eicher JC; Meneveau N; Lusson JR; Bertrand B; Schleich JM; Godart F; Thambo JB; Leborgne L; Michel P; Pierard L; Turc G; Barthelet M; Charles-Nelson A; Weimar C; Moulin T; Juliard JM; Chatellier G;
    N Engl J Med; 2017 Sep; 377(11):1011-1021. PubMed ID: 28902593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patent foramen ovale (PFO) closure versus medical therapy for prevention of recurrent stroke in patients with prior cryptogenic stroke: A systematic review and meta-analysis of randomized controlled trials.
    Akobeng AK; Abdelgadir I; Boudjemline Y; Hijazi ZM
    Catheter Cardiovasc Interv; 2018 Jul; 92(1):165-173. PubMed ID: 29602258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patent Foramen Ovale and Cryptogenic Stroke or Transient Ischemic Attack: To Close or Not to Close? A Systematic Review and Meta-Analysis.
    Lattanzi S; Brigo F; Cagnetti C; Di Napoli M; Silvestrini M
    Cerebrovasc Dis; 2018; 45(5-6):193-203. PubMed ID: 29649819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Closure versus medical therapy for preventing recurrent stroke in patients with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack.
    Li J; Liu J; Liu M; Zhang S; Hao Z; Zhang J; Zhang C
    Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD009938. PubMed ID: 26346232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Percutaneous closure versus medical therapy for stroke with patent foramen Ovale: a systematic review and meta-analysis.
    Zhang XL; Kang LN; Wang L; Xu B
    BMC Cardiovasc Disord; 2018 Mar; 18(1):45. PubMed ID: 29499641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcatheter closure of patent foramen ovale for secondary prevention of ischemic stroke: Quantitative synthesis of pooled randomized trial data.
    Hakeem A; Cilingiroglu M; Katramados A; Boudoulas KD; Iliescu C; Gundogdu B; Marmagkiolis K
    Catheter Cardiovasc Interv; 2018 Nov; 92(6):1153-1160. PubMed ID: 29332308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patent Foramen Ovale Closure Versus Medical Therapy for Cryptogenic Stroke: Meta-Analysis of Randomised Trials.
    Wang TKM; Wang MTM; Ruygrok P
    Heart Lung Circ; 2019 Apr; 28(4):623-631. PubMed ID: 29602754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is Patent Foramen Ovale Closure More Effective Than Medical Therapy in Preventing Stroke Recurrence in Patients With Cryptogenic Stroke?: A Critically Appraised Topic.
    Valencia-Sanchez C; Fortuin FD; Sweeney JP; Ingall TJ; Marks LA; Wingerchuk DM; O'Carroll CB
    Neurologist; 2018 Sep; 23(5):175-180. PubMed ID: 30169372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes of secondary prevention strategies for young patients with cryptogenic stroke and patent foramen ovale.
    Danese A; Stegagno C; Tomelleri G; Piccoli A; Turri G; Carletti M; Variola A; Anselmi M; Mazzucco S; Ferrara A; Bovi P; Micheletti N; Cappellari M; Monaco S; Vassanelli C; Ribichini F;
    Acta Cardiol; 2017 Aug; 72(4):410-418. PubMed ID: 28705105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.